Recent Updates
Recently added Catalysts
COYA Positive Sentiment

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Tuesday, September 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Coya Therapeutics has announced the enrollment of its 100th participant in the Phase 2/3 ALSTARS Trial for COYA 302, a treatment for amyotrophic lateral sclerosis (ALS). This trial evaluates the efficacy of a combination of low-dose IL-2 and CTLA-4 Ig. The milestone reflects progress in developing therapies for neurodegenerative disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Coya Therapeutics has reached a significant milestone with 100 participants enrolled.
  • The trial focuses on a promising treatment for amyotrophic lateral sclerosis (ALS).
  • COYA 302 combines innovative biologics aimed at enhancing T-cell function.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
2%
average across 2 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
COYA 302
Phase 2 · Amyotrophic Lateral Sclerosis (ALS)

Full Press Release Details

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that the 100th patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis (AL

Frequently Asked Questions

What is the ALSTARS Trial?

The ALSTARS Trial is a Phase 2/3 clinical study evaluating COYA 302 for ALS treatment.

How many participants have been enrolled in the trial?

Coya Therapeutics has announced the enrollment of its 100th participant.

What does COYA 302 consist of?

COYA 302 is a combination of proprietary low-dose IL-2 and CTLA-4 Ig.

What condition is COYA 302 targeting?

COYA 302 is aimed at treating amyotrophic lateral sclerosis (ALS).

ShareAdd on Google
Tags: COYA Viatris Investor Conferences Healthcare Coya Therapeutics COYA 302 ALSTARS Trial amyotrophic lateral sclerosis ALS
Last updated: Sep 15, 2026

Biotech snapshot

Cash runway
$43M liquidity · $2M/mo burn
~17 mo
Low dilution risk
Lead asset
COYA 302Phase 2
Amyotrophic Lateral Sclerosis (ALS) →

Catalyst track record

+10%
best trade around COYA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for COYA.

See every catalyst's timing & PoA →